Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05224063 · ClinicalTrials.gov registry record · NA
Probing the Dorsolateral Prefrontal Cortex and Central Executive Network for Improving Neuromodulation in Depression
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 50
- Enrollment target
NCT05224063: Completed NA study, sponsored by Stanford University.
NCT05224063 is a NA study that has completed, run by Stanford University. The registered enrollment target is 50 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05224063, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
Study Summary
Depression is a highly prevalent condition characterized by persistent low mood, energy, and activity that can affect one's thoughts, mood, behavior, and sense of well-being. Repetitive transcranial magnetic stimulation (rTMS), a non-invasive neuromodulatory technique, is an effective treatment for depression when targeting the dorsolateral prefrontal cortex (dlPFC) of the central executive network (CEN). However, remission rates are suboptimal and individual methods to target the dlPFC are lacking. In this study, we will enroll 50 patients with major depression and in a single rTMS 'dose,' prospective, randomized, double-blind, cross-over design will assess whether rTMS targeted to an individual's central executive network (CEN) assessed by single pulse TMS can enhance network modulation. If successful, this work will lead to a clinical rTMS trial comparing this personalized targeting approach against standard rTMS.
Primary Outcome
TMS-evoked EEG responses were measured before and after intermittent theta burst stimulation (iTBS) using single-pulse TMS probes applied to prefrontal and parietal regions. The primary measure was the change in early TMS-evoked potentials (TEPs), defined as the peak-to-peak amplitude within approximately 20-50 ms following the TMS pulse. Changes in electrophysiological responses were assessed across timepoints (pre-intervention, early post-intervention, and late post-intervention) and compared
Interventions
- DEVICE Sham rTMS
- DEVICE Individualized CEN-targeted rTMS
- DEVICE Neuronavigated rTMS
- DEVICE Scalp-targeted rTMS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-01-01 |
| Est. Completion | 2025-03-27 |
| Phase | NA |
What the finished NCT05224063 record still lists
NCT05224063 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 4 interventions - of which Sham rTMS is the first listed.
NCT05224063 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05224063 about?
NCT05224063 is a clinical study titled "Probing the Dorsolateral Prefrontal Cortex and Central Executive Network for Improving Neuromodulation in Depression". Depression is a highly prevalent condition characterized by persistent low mood, energy, and activity that can affect one's thoughts, mood, behavior, and sense of well-being. Repetitive transcranial magnetic stimulation (rTMS), a non-invasive neuromodulatory technique, is an effective treatment for ...
What is the current status of trial NCT05224063?
This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2023-01-01. Estimated completion is 2025-03-27.
What interventions are being tested in trial NCT05224063?
The interventions under investigation include: Sham rTMS (DEVICE), Individualized CEN-targeted rTMS (DEVICE), Neuronavigated rTMS (DEVICE), Scalp-targeted rTMS (DEVICE).
Who is sponsoring clinical trial NCT05224063?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05224063's enrollment target sits among peer trials
50 1279th of 2000 higher than 622 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI